Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 8/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798750 | 0.90 | MAOA (0.46) | KIF11MAOADYRK1AALKHTR1A | |
| SCHEMBL7250477 | 0.86 | HTR2A (0.50) | MAOADYRK1AHTR2AHTR1DRXFP1 | |
| SCHEMBL20434631 | 0.86 | KIF11 (0.50) | KIF11MAOADYRK1AHTR1AHTR1B | |
| SCHEMBL7250798 | 0.84 | KIF11 (0.49) | KIF11MAOADYRK1ARXFP1 | |
| SCHEMBL1795837 | 0.84 | PARP1 (0.49) | KIF11MAOADYRK1AHTR2AHTR1A | |
| SCHEMBL5195511 | 0.83 | MAOA (0.44) | MAOADYRK1AALKHTR1AHTR1D | |
| SCHEMBL7108868 | 0.83 | KIF11 (0.54) | KIF11MAOA | |
| SCHEMBL20434641 | 0.82 | KIF11 (0.53) | KIF11MAOADYRK1A | |
| SCHEMBL1793765 | 0.82 | HTR1A (0.45) | KIF11MAOADYRK1AHTR2AHTR1A | |
| SCHEMBL7253761 | 0.81 | PARP1 (0.45) | KIF11MAOADYRK1AHTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | claimed |
| EP-1238973-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-09-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | KIF11 4358/4885MAOA 2743/4885DYRK1A 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.